ArticleJournal of breast cancer2025
Reoperation Versus Dose-Escalated Radiotherapy for Ductal Carcinoma
Article in Journal of breast cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of this study was to compare local recurrence (LR) rates in patients with ductal carcinoma
methodsThis single-center, retrospective study included patients diagnosed with invasive ductal carcinoma (IDC) who underwent BCS at National Cancer Center between 2014 and 2020. Patients with DCIS at the surgical margin were eligible for inclusion. Those who did not undergo re-excision received whole-breast radiotherapy with an escalated tumor bed boost of 15 Gy in five fractions. The 5-year breast cancer recurrence rates were estimated using the Kaplan-Meier method, and prognostic factors were evaluated using univariate and multivariate Cox proportional hazards regression models.
resultsAmong the 235 eligible patients, 115 underwent re-excision (Re-excision + group), and 120 did not (Re-excision - group). With a median follow-up of 5.0 years (range, 3.1-6.6 years), the 5-year LR rate was 6.1% in the Re-excision + group and 5.8% in the Re-excision - group (log-rank
conclusionIn cases where DCIS was present at the surgical margin after BCS, re-excision was not associated with a lower LR rate compared with dose-escalated radiotherapy. This study did not assess late radiation-related toxicities, such as breast fibrosis, which are important considerations for treatment decision-making. These findings should be interpreted with caution because of the retrospective design and limited event rate. Further prospective studies are warranted to determine optimal management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.